Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Tassi who wrote (54060)	4/4/2000 9:56:00 AM
From: Anthony@Pacific	Read Replies (1) \| Respond to of 122087

Dude I have no power I just buy and sell and post ..thats all I can do But Myn 85% short portfolio is doiong well

To: Tassi who wrote (54060)	4/4/2000 7:00:00 PM
From: rupers	Respond to of 122087

Tassi - CEGE will rebound by end-month - big, IMO. Maybe old news to you, but: The $ 194 million they got from ABGX sale will be reported as "earnings" in their annual statement due out during week of April 24th. They have lots of net loss carry forwards to apply to the tax bill on the profits. Will see a single digit P/E ratio for biotech (that'll grab some attention). Doesn't take a math wiz to see value per share with 34 million shares outstanding, and they still have 2.5 million shares of ABGX in their coffers (worth about $ 300 million now). CEGE is aggressively looking for acquisition of another biotech with a product/product line near ready for commercial distribution. CEGE will also have some news on their clinical trials for clinical studies cancer symposium in May. IMO, buy this son of a gun cheap while you can.